Understanding Multiple Myeloma

Multiple myeloma is incurable, and patients can eventually become refractory to multiple classes of treatment

Proteasome inhibitors

Immunomodulatory agents

Anti-CD38 monoclonal antibodies

Patients with triple-class refractory multiple myeloma can have more progressive disease, poor prognosis, and few treatment options remaining.

Patients can continue to progress and require additional therapies.^1,3,4

CD38, cluster of differentiation 38.

References:

Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1-7.
Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017-1025.
Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396-406.
Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol.
2016;175(2):252-264.